A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with wet Age-Related Macular Degeneration (Velodrome)
- Conditions
- eovascular age-related macular degeneration (nAMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2020-001313-20-DE
- Lead Sponsor
- F. Hoffman-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 442
General inclusion criteria:
? Age >= 50 years
? For women of childbearing potential: agreement to remain abstinent or use contraception and must remain abstinent or use contraceptive
methods with a failure rate of <1% per year during the study, within 3 months after the final intravitreal ranibizumab injection and for 1 year
after the final implant refill-exchange procedure or implantation of the PDS
Ocular inclusion criteria
? Initial diagnosis nAMD within 9 months prior to the screening visit
? Previous treatment with at least three anti- vascular endothelial growth factor (VEGF) intravitreal injections for nAMD per standard of care within
6 months prior to the screening visit
? Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis
? Availability of historical visual acuity data prior to the first anti-VEGF treatment for nAMD until the time of study enrollment
? BCVA of 34 letters or better, using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters at
screening and enrollment visits
? With any subtype of nAMD lesions
o nAMD lesions at the time of diagnosis must involve the macula (6-mm diameter centered at the fovea)
? Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of fundus
photography, fluorescein angiography, fundus autofluorescence image, and OCT images
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 62
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 380
Prior Ocular Treatment
o Study Eye
? History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
? Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary thermotherapy
? Previous treatment with corticosteroid intravitreal injection, intraocular device implantation, previous laser used for AMD treatment
? Prior treatment with intravitreal treatments for Geographic Atrophy (at any time prior to the screening visit)
? Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the enrollment visit
? Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant
o Either Eye
?Prior treatment with brolucizumab (at any time prior to the screening visit)
?Prior gene therapy for nAMD
?Prior participation in a clinical trial involving any therapies for nAMD, within 9 months from the time of nAMD diagnosis, CNV Lesion Characteristics
? Patients who meet any of the following exclusion criteria related to CNV lesion
o Study Eye
? Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area in size at screening
? Subfoveal fibrosis or subfoveal atrophy
o Either Eye
? CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia Concurrent Ocular Conditions
? Patients who meet any of the following exclusion criteria related to concurrent ocular conditions
o Study Eye
? Retinal pigment epithelial tear
? Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
? Active intraocular inflammation
? History of vitreous hemorrhage, rhegmatogenous retinal detachment, pars plana vitrectomy surgery, rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit
? Aphakia or absence of the posterior capsule
? Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia
? Preoperative refractive error that exceeded 8 diopters of myopia, for patients who have undergone prior refractive or cataract surgery in the study eye
? Intraocular surgery within 3 months preceding the enrollment visit
? Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
? History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
? History of corneal transplant
? Non-functioning fellow (non-study) eye
o Either Eye
Patients who meet the following exclusion criterion for the either eye at both the screening and enrollment visits will be excluded from study entry
? Any history of uveitis requiring treatment
? Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis Concurrent Systemic Conditions
? Uncontrolled blood pressure
? History of stroke within the last 3 months prior to informed consent
? Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed consent
? History of myocardial infarction within the last 3 months prior to informed consent, other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable susp
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method